Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.

@article{Rich2006ShorttermSA,
  title={Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.},
  author={R. Michael Rich and Philip J. Rosenfeld and Carmen A. Puliafito and Sander R. Dubovy and Janet L. Davis and Harry W. Flynn and Serafin Gonzalez and William J Feuer and Richard Chun-Hung Lin and Geeta A Lalwani and Jackie K Nguyen and G. S. Yashavanth Kumar},
  journal={Retina},
  year={2006},
  volume={26 5},
  pages={495-511}
}
PURPOSE To evaluate the safety and efficacy of intravitreal bevacizumab (Avastin, Genentech Inc.) for the treatment of neovascular age-related macular degeneration (ARMD). METHODS A retrospective review was performed on consented patients with neovascular ARMD receiving intravitreal bevacizumab therapy. All patients received intravitreal bevacizumab at baseline with additional monthly injections given at the discretion of the treating physician. At each visit, a routine Snellen visual acuity… CONTINUE READING

From This Paper

Topics from this paper.
180 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 180 extracted citations

Similar Papers

Loading similar papers…